Literature DB >> 8635527

In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation.

T Watanabe1, G S Brown, L S Kelsey, Y Yan, J D Jackson, C Ewel, A Kessinger, J E Talmadge.   

Abstract

Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) demonstrated hemato-protective activity in mice after sublethal irradiation (7 GY). Bone marrow interleukin-3 (IL-3)-responsive colony-forming cells (CFC and high proliferative potential colony-forming cells (HPP-CFC) were significantly (p < 0.05) increased by day 10 after irradiation in mice receiving a continuous infusion of 1000 ng/day of AcSDKP compared to irradiated control mice. The maximum protective effect for bone marrow progenitors was achieved when AcSDKP was administered for 3 days beginning 24 hours before irradiation. Other dosages and schedules in relationship to irradiation were less active. Further, when granulocyte colony-stimulating factor (G-CSF) was administered for 10 days beginning 24 hours before irradiation. Other dosages and schedules in relationship to irradiation were less active. Further, when granulocyte colony-stimulating factor (G-CSF) was administered for 10 days after AcSDKP infusion in irradiated mice, significantly increased numbers of IL-3 responsive CSF-only control mice. In addition, platelets were significantly (p < 0.05) increased in mice receiving AcSDKP and G-CSF on days 18 and 21 after irradiation compared with mice receiving G-CSF alone. We conclude that ACSDKP has a radioprotective effect in vivo for progenitor cells, and that time of initiation and duration of AcSDKP administration relative to irradiation are crucial for these effects. Further, AcSDKP has a significant additive protective effect not only for progenitor cells but also for platelets when given in combination with G-CSF. We suggest that these in vivo observations provide a basis on which to design optimal clinical hypothesis and protocols.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635527

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

Review 1.  The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis.

Authors:  Xiao Z Shen; Kenneth E Bernstein
Journal:  Cell Cycle       Date:  2011-05-01       Impact factor: 4.534

2.  RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.

Authors:  V Dive; J Cotton; A Yiotakis; A Michaud; S Vassiliou; J Jiracek; G Vazeux; M T Chauvet; P Cuniasse; P Corvol
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

3.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

4.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

5.  Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

Authors:  Jean Boutonnat; Anne-Marie Faussat; Jean-Pierre Marie; Jérôme Bignon; Johanna Wdzieczak-Bakala; Magali Barbier; Josiane Thierry; Xavier Ronot; Pierre-Emmanuel Colle
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

Review 6.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.